Enbezotinib is under clinical development by Turning Point Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Enbezotinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TPX-0046 is under development for the treatment of cancers including non-small cell lung cancer, colorectal cancer, papillary thyroid, medullary thyroid cancer, and other solid tumors with abnormal RET gene. It is administered through oral route in the form of capsule. The drug candidate is a new chemical entity. It acts by targeting RET (ret proto-oncogene) kinase and SRC.
Turning Point Therapeutics overview
Turning Point Therapeutics (TP therapeutics) is a biopharmaceutical company. It designs and develops clinical stage small molecule, targeted oncology therapies to address key limitations of existing lung cancer therapies. Its pipeline products include Repotrectinib, macrocyclic tyrosine kinase inhibitor, TPX-0022, multi-targeted kinase inhibitor, TPX-0046, a multi-targeted orally bioavailable TKI, TPX – 013 and ALK inhibitor. TP therapeutics also provides clinical trial activities such as TRIDENT-1 and compassionate use programs. The company’s macrocyclic platform addresses the issues of emerging treatment resistance and toxicities that limit duration of treatment. It operates in the US and Switzerland. TP Therapeutics is headquartered in San Diego, California, the US.
For a complete picture of Enbezotinib’s drug-specific PTSR and LoA scores, buy the report here.